Core Insights - OrthoPediatrics Corp. announced the appointment of Kelly Fischer to its Board of Directors, effective August 8, 2025, alongside the retirement of Terry Schlotterback from the board on the same date [1][2]. Group 1: Board Changes - Kelly Fischer brings extensive financial leadership experience from her role as Senior Vice President and Chief Financial Officer at Cook Medical, a multibillion-dollar medical device company [2]. - Terry Schlotterback has served over fifteen years as a Director and Chairman of the Board, contributing significantly to the company's establishment as a leader in pediatric orthopedics [2]. Group 2: Company Strategy and Vision - Kelly Fischer expressed her commitment to supporting OrthoPediatrics' strategy to increase market share, launch new technologies, and expand the specialty bracing franchise efficiently [3]. - The company aims to help one million children by advancing its offerings in the pediatric orthopedic field [3]. Group 3: Company Overview - Founded in 2006, OrthoPediatrics focuses exclusively on pediatric orthopedics, offering over 80 products across trauma and deformity, scoliosis, and sports medicine categories [4]. - The company's global sales organization distributes its products in the United States and over 70 countries, emphasizing its commitment to improving the lives of children with orthopedic conditions [4].

OrthoPediatrics (KIDS) FY Conference August 13, 2025 11:00 AM ET Speaker0Good morning, everyone, and thank you for joining us at this year's Canaccord Genuity Global Growth Conference. My name is Caitlin Cronin, and I'm on the medical device team here at Canaccord Genuity. I'm joined today by OrthoPediatrics, a medical device company dedicated to developing orthopedic solutions exclusively for the pediatric population. And with me today are Dave Bailey, CEO, and Fred Hite, CFO. And before we begin, I want t ...

OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) Commission file number: 001-38242 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OrthoPediatrics Corp. (Exact name of registrant as specified in its charter) (State or other jurisdiction ...

Core Insights - OrthoPediatrics reported revenue of $61.08 million for the quarter ended June 2025, reflecting a year-over-year increase of 15.7% [1] - The company's EPS was -$0.11, an improvement from -$0.23 in the same quarter last year, with a surprise of +35.29% compared to the consensus estimate of -$0.17 [1] - The revenue fell short of the Zacks Consensus Estimate of $61.7 million, resulting in a surprise of -1% [1] Revenue Performance - Product sales in the Trauma and deformity category reached $41.67 million, below the three-analyst average estimate of $44.58 million, marking a year-over-year increase of 10.3% [4] - Sales in the Sports medicine/other category were $0.91 million, significantly lower than the $1.18 million average estimate, representing a year-over-year decline of 32.9% [4] - Scoliosis product sales amounted to $18.52 million, exceeding the average estimate of $15.95 million, with a year-over-year increase of 35.4% [4] Stock Performance - Over the past month, OrthoPediatrics shares have returned -3.3%, contrasting with the Zacks S&P 500 composite's +1% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]

Company Performance - OrthoPediatrics reported a quarterly loss of $0.11 per share, better than the Zacks Consensus Estimate of a loss of $0.17, and an improvement from a loss of $0.23 per share a year ago, resulting in an earnings surprise of +35.29% [1] - The company posted revenues of $61.08 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 1%, but showing an increase from year-ago revenues of $52.8 million [2] - Over the last four quarters, OrthoPediatrics has surpassed consensus EPS estimates just once and topped consensus revenue estimates two times [2] Stock Outlook - OrthoPediatrics shares have declined approximately 11.4% since the beginning of the year, contrasting with the S&P 500's gain of 7.6% [3] - The company's earnings outlook is mixed, with the current consensus EPS estimate for the coming quarter at -$0.14 on revenues of $63.72 million, and -$1.24 on revenues of $239.45 million for the current fiscal year [7] Industry Context - The Medical - Instruments industry, to which OrthoPediatrics belongs, is currently ranked in the bottom 37% of over 250 Zacks industries, indicating potential challenges ahead [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact OrthoPediatrics' stock performance [5]

Financial Data and Key Metrics Changes - In Q2 2025, worldwide revenue reached $61.1 million, a 16% increase compared to 2024, driven by strong performance across Trauma and Deformity, Scoliosis, and OPSB [26][27] - US revenue was $48.1 million, a 17% increase from 2024, representing 79% of total revenue [26] - International revenue totaled $12.9 million, reflecting a 12% growth compared to 2024, accounting for 21% of total revenue [27] - Gross profit margin decreased to 72% from 77% in 2024, primarily due to higher 7D growth and increased international set sales [28] - Adjusted EBITDA improved to $4.1 million, a 50% increase from $2.6 million in 2024 [32] Business Line Data and Key Metrics Changes - Trauma and Deformity global revenue was $41.7 million, a 10% increase year-over-year, driven by PMP femur, PMP tibia, DF2, and OPSB [27] - Scoliosis global revenue reached $18.5 million, a 35% increase compared to the prior year, driven by increased sales of Response, ApiFix, and 7D Technology [27][28] - The OPSB business grew over 20%, surpassing initial guidance for 2025 territory expansion [14][20] Market Data and Key Metrics Changes - International sales were solid, particularly in Europe and the Middle East, with strong surgical demand [6][23] - The company achieved its first EU MDR approval through LP Canada, which is expected to catalyze future growth [24] Company Strategy and Development Direction - The company is focused on expanding its OPSB strategy through territory expansion, accelerated R&D, and scaling its sales force [14][20] - The 3P pediatric plating platform is expected to enhance market share in trauma and limb deformity, with multiple new systems planned for launch [13][89] - The company is committed to helping more children and significantly growing revenue while improving adjusted EBITDA and reducing cash burn [35] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving strong momentum throughout 2025, driven by successful scaling of OPSB and innovative product launches [8][9] - The company raised its revenue guidance for 2025 to a range of $237 million to $242 million, representing year-over-year growth of 16% to 18% [33] Other Important Information - The company hosted 182 unique training experiences for over 3,420 healthcare professionals in Q2 2025 [25] - The company ended Q2 2025 with $72.2 million in cash, short-term investments, and restricted cash [32] Q&A Session Summary Question: Can you discuss the clinic strategy and the performance of existing clinics? - Management noted that existing clinics are seeing growth due to investments made on the sales side, while new Greenfield clinics are contributing to revenue but not yet at maximum volume [39][40] Question: Can you provide insights on the Scoliosis and T&D business growth expectations for the second half of the year? - Management expects Scoliosis growth to remain strong, potentially exceeding overall company growth, while T&D growth may be lighter due to previous quarter comparisons [45] Question: What caused the selective case slowdown in the limb deformity segment? - Management indicated that the volume was lighter in the first part of Q2 but rebounded strongly in June, attributing the fluctuation to normal business ebbs and flows [49][50] Question: How is the international product expansion strategy structured? - Management stated that international growth is expected to outpace US growth, with new product launches planned on a quarterly basis following EU MDR approvals [64][66] Question: What are the expectations for the trauma portfolio and potential product gaps? - Management highlighted the introduction of the 3P system as a significant opportunity to fill gaps in the trauma and deformity market, with plans for multiple system launches over the next few years [88][89]

2025 Investor Presentation www.OrthoPediatrics.com Disclaimer Forward-Looking Statements All statements, other than statements of historical facts, contained in this quarterly report, including statements regarding our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business, operations and financial performance and condition, are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "ma ...

OrthoPediatrics Corp. Reports Second Quarter 2025 Financial Results and Increases Full Year 2025 Revenue Guidance Second Quarter 2025 Revenue Surpasses $60 million for the First Time in Company History, and Increased Adjusted EBITDA by 58% year- over-year WARSAW, Ind., August 5, 2025 -- OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its financial results for the second quarter ended Jun ...

Core Insights - OrthoPediatrics Corp. reported a record revenue of $61.1 million for Q2 2025, marking a 16% increase year-over-year, with adjusted EBITDA rising by 58% to $4.1 million [1][4][8] Financial Performance - Total revenue for Q2 2025 was $61.1 million, up from $52.8 million in Q2 2024, driven by strong growth in Scoliosis, Trauma, and OPSB products [4][8] - U.S. revenue reached $48.1 million, a 17% increase from $41.2 million in the same quarter last year, accounting for 79% of total revenue [4][8] - International revenue was $12.9 million, a 12% increase from $11.6 million year-over-year [4][8] - Trauma and Deformity revenue grew by 10% to $41.7 million, while Scoliosis revenue surged by 35% to $18.5 million [5][8] - Gross profit for Q2 2025 was $44.0 million, an 8% increase from $40.8 million in Q2 2024, with a gross profit margin of 72% [6][8] Operating Expenses - Total operating expenses increased by 18% to $54.7 million, primarily due to restructuring charges and increased personnel costs [7][8] - Sales and marketing expenses rose by 15% to $19.1 million, driven by higher sales commissions [9][8] - General and administrative expenses increased by 11% to $30.4 million, reflecting higher non-cash stock compensation and additional personnel [10][8] Net Loss and Cash Flow - The net loss for Q2 2025 was $7.1 million, compared to a loss of $6.0 million in Q2 2024, with a GAAP diluted loss per share of ($0.30) [12][8] - Non-GAAP diluted loss per share improved to ($0.11) from ($0.23) year-over-year [12][8] - Cash, cash equivalents, and short-term investments totaled $72.2 million as of June 30, 2025, up from $70.8 million at the end of 2024 [13][8] Business Expansion - The company expanded its OrthoPediatrics Specialty Bracing Division (OPSB) with new clinics and entered two new territories, including its first international operation in Ireland [8] - Full-year 2025 revenue guidance was raised to a range of $237.0 million to $242.0 million, indicating a growth of 16% to 18% compared to the previous year [14][8]

Core Insights - OrthoPediatrics Corp. is expanding its OrthoPediatrics Specialty Bracing (OPSB) division with new clinics and entry into new territories, including California, Ohio, and Colorado [1][6] - The company is slightly ahead of its planned entry into four new target markets for 2025, aiming to provide better bracing and O&P care to children globally [3][4] - The expansion includes Acquihire opportunities with new operations in New York and Ireland, marking the first international market for OPSB [2][6] Company Overview - Founded in 2006, OrthoPediatrics focuses exclusively on pediatric orthopedics, offering over 80 products across trauma and deformity, scoliosis, and sports medicine categories [5] - The company distributes its products in the United States and over 70 countries, emphasizing its commitment to improving the lives of children with orthopedic conditions [5] Market Expansion - The new clinic in California targets the Los Angeles market, providing access to millions of potential pediatric patients [6] - The Dayton, OH clinic is located within Dayton Children's Hospital, enhancing local access to skilled clinicians [6] - The expansion into Ireland complements OrthoPediatrics' existing implant business and opens opportunities for further growth in Europe [6]